Vandefitemcel

N/A

Report date: 2024/03/05 14:42:17

Base Information

Drug NameVandefitemcel
Drug Alias NameModified bone marrow derived mesenchymal stem cells(SanBio)SB-623OT-1601
ClassificationCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacementsNerve growth factor modulators
TargetsNerve growth factor
Therapy Area/IndicationsIschemic StrokeGeographic AtrophyRetinitis Pigmentosa +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineHong Kong +[5] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPreclinical
Originator CompaniesSanbio
China Registration ClassN/A

Develop Information

Active CompaniesSanBio Co LtdSanbio IncOcumension (Hong Kong) Ltd
Inactive CompaniesSumitomo Pharma America Inc
Active IndicationsGeographic AtrophyRetinitis PigmentosaSpinal Cord Injuries +[7] 
Inactive IndicationsIschemic Stroke

Other Information

ATC CodeN/A
Related LinksN/A